It is also being evaluated as a potential treatment for ankylosing spondylitis, and the company plans to begin registration-enabling studies in atopic dermatitis, ulcerative colitis, and giant cell arteritis
The cost watchdog's ruling means it is unlikely that patients with giant cell arteritis
will have access to the treatment any time soon.
Giant cell arteritis
(GCA) is the most common vasculitis of the elderly, primarily affecting individuals over 50 years of age.
12 If the patient was diagnosed with giant cell arteritis
, which of the following is correct?
Takayasu's aortoarteritis (TA) is a chronic, progressive, idiopathic, occlusive arteritis
of the aorta and aortic arch branches.
Giant cell arteritis
(GCA) is an inflammatory lesion of the large- and medium-sized arteries, which usually involves the cranial arteries of older women.
It is recommended for temporal arteritis
(inflamed arteries), varicose veins, lumbago, sciatica, rheumatism, intermittent claudication (lameness in the legs due to poor blood supply), restlessness in children, sleeplessness, whooping cough, chronic bronchitis and parasthesia (chronic pins and needles).
THE FOOD AND DRUG Administration has approved subcutaneous tocilizumab (Actemra) for the treatment of giant cell arteritis
Todays FDA decision means people living with giant cell arteritis
will, for the first time, have an FDA-approved treatment option for this debilitating disease, said Sandra Horning, MD, Chief Medical Officer and Head of Global Product Development.
(TA) is a medium and large vessel vasculitis of unknown etiology characterized by chronic granulomatous inflammation of the vessel wall leading to thickening, stenosis, dilatation, and/or aneurysm of the affected vessel.
These findings are consistent with moderate multifocal to coalescing granulomatous arteritis
There are also about 11,000 people with the more serious condition giant cell arteritis
, a condition in which medium and large arteries, usually in the head and neck, become inflamed.